EN
BACKGROUND AND AIMS: Schizophrenia is a devastating psychiatric disorder that impairs mental and social functioning and affects approximately 1% of the world’s population. Although the atypical antipsychotics have some efficacy in alleviating social dysfunction in schizophrenic patients, this effect is small and mechanisms of this action are still unknown. Moreover, preclinical and clinical studies have suggested that the antidepressant-induced augmentation of atypical antipsychotics activity may efficiently improve the treatment of negative and some cognitive symptoms of schizophrenia. In the present study, we aimed to evaluate the effect of the atypical antipsychotic drug aripiprazole (ARI) and the antidepressant mirtazapine (MIR) or escitalopram (ESC), given separately or jointly, on the MK-801 (a NMDA receptor antagonist)-induced deficits in the social interaction test (an animal test modeling some negative symptoms of schizophrenia). METHODS: The experiments were conducted on male Wistar rats (185–200 g). The social interaction was measured 4 h after the subcutaneously administration of MK-801 (0.1 mg/kg), and 60 or 30 min after injection of the antidepressant and ARI, respectively. RESULTS: The present results showed that MK-801 (0.1 mg/kg) induced deficits in both parameters studied, i.e. the number of episodes and the time of interactions. ARI at a higher dose (0.3 mg/ kg) reversed that effect. Co-treatment with an ineffective dose of ARI (0.03 mg/kg) and MIR or ESC (5 mg/kg) abolished the deficits evoked by MK-801, and this effect was partly blocked by a 5-HT1A receptor antagonist (WAY 100635, 0.1 mg/kg) or a dopamine D1 receptor antagonist (SCH23390, 0.5 mg/kg). CONCLUSIONS: The obtained results suggest that the enhancement of antipsychotic-like effect of ARI by antidepressants on the MK-801-induced deficits in the social interaction test may be associated with serotonin 5-HT1A and dopamine D1 receptors.